The Rheumatologist
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
  • Technology
    • Electronic Health Records
    • Apps
    • Information Technology
  • Resources
    • Issue Archives
    • Events
    • Multimedia
      • Audio
      • Video
    • From the College
    • American College of Rheumatology
    • Rheumatology Research Foundation
    • Arthritis & Rheumatology
    • Arthritis Care & Research
    • Treatment Guidelines
    • Research Reviews
    • Annual Meeting
      • Abstracts
      • Meeting Reports
    • Rheumatology Image Bank
    • ACR ExamRheum
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / The ACR Agenda in D.C.: Where We Stand in Mid-April

The ACR Agenda in D.C.: Where We Stand in Mid-April

April 19, 2017 • By Angus B. Worthing, MD, FACP, FACR

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Editor’s note: This blog by Dr. Worthing originally appeared on the ACR’s Advocacy Listserv.

You Might Also Like
  • The ACR Announces Advocacy Priorities for 2016
  • AHCA, ACR Health Policy & More
  • Where the Presidential Candidates Stand on Key Healthcare Issues

Here’s a perspective on the current climate in which your government affairs team works. As you read this list of observations, imagine you’re a lawmaker and try to find where the ACR’s agenda fits into the current landscape:

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
  1. Washington is highly politicized. Interparty rancor grew with the highly politicized SCOTUS [Supreme Court of the United States] confirmation and removal of the filibuster by Republicans. Also, intraparty conflict within the Republican party was stoked when moderates and Freedom Caucus members did not support the Ryan/Trump healthcare bill. (As you probably know, the bill failed; now, it’s a zombie—neither dead nor alive; more below.)
  2. Institutions are weakening. Multiple global and domestic institutions are losing support, recognition, power or relevance. Take your pick: NATO, the Senate, SCOTUS, U.S. federal agencies, election campaigns. Leaders on both sides of the aisle are concerned about this.
  3. People are being investigated. The Senate and FBI are investigating Russia and the Trump 2016 campaign regarding the presidential election. This creates work for all sides, possibly limiting the focus on other legislative and executive initiatives, possibly influencing Trump’s behavior and testing alliances in the balance of power with third parties (e.g., ISIS, Syria, Iran, Turkey).
  4. Have you noticed any relevance to rheumatology yet? Moving on: the U.S. bombed Syria after Syrians were gassed in the ongoing war there. Civil war? Proxy war? Secretary of State Tillerson is in Russia asking [Russia] to stop supporting Syria’s dictator (see #3 above). He could use the support of NATO (see #2).
  5. There isn’t a clear overarching White House agenda. After a flurry of executive orders and a failure to pass the healthcare bill, priorities are unclear. And with infighting between senior White House staff, there are no high-level interlocutors to convey policy.
  6. U.S. government funding ends April 28. This will probably force some bipartisanship to renew a continuing resolution (CR) and/or a budget, while other activity stalls. The $17 trillion debt and White House proposals to raise military spending may pressure leaders to reduce domestic discretionary spending (research) and entitlement programs (healthcare). Aha! There’s the beginning of the ACR agenda.

My apologies if the point is heavy handed, but long story short, we rheumatology advocates can be forgiven for feeling like we’re a little low on the priority list nowadays. But rest assured, your team is hard at work. Also, lawmakers are continually campaigning and want to start a relationship with us. The relationships we’ve nurtured through RheumPAC and our commonsense and nonpartisan initiatives have never been more critical.

Pages: 1 2 3 4 | Single Page

Filed Under: Legislation & Advocacy, Professional Topics Tagged With: ACR Government Affairs Committee, Capitol Hill, government funding, H1B visas, immigration, White House agenda, Zombie Healthcare Bill

You Might Also Like:
  • The ACR Announces Advocacy Priorities for 2016
  • AHCA, ACR Health Policy & More
  • Where the Presidential Candidates Stand on Key Healthcare Issues
  • ACR Publishes National Research Agenda for 2016–2020

ACR/ARP Annual Meeting

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Annual Meeting site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR/ARP Meeting Abstracts

Browse and search abstracts from the ACR/ARP Annual Meetings going back to 2012.

Visit the ACR/ARP Meeting Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2019 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.